An abnormal MMSE result does not diagnose dementia. It signals the need for a fuller evaluation to confirm cognitive decline, assess daily functioning, and look for other causes. The MMSE, or Mini-Mental State Examination, is a brief cognitive screening test. The Alzheimer's Association states that people who do not pass a brief screen need further evaluation or specialist referral before mild cognitive impairment or dementia can be diagnosed in its cognitive assessment guidance.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does an abnormal MMSE mean?
- What happens during the clinical evaluation?
- Which other causes need to be checked?
- Will an MRI or CT scan diagnose Alzheimer's disease?
- When are specialists or Alzheimer biomarkers appropriate?
What does an abnormal MMSE mean?
The result shows that the person had difficulty with one or more tasks on the screen. It does not explain why the difficulty occurred or establish a particular disease. The clinician must determine whether there is objective cognitive decline and whether it affects everyday activities.
That distinction matters when deciding whether symptoms fit mild cognitive impairment, dementia, or another condition. One result should therefore prompt investigation, not an immediate assumption of Alzheimer's disease. The next steps depend on the person's symptoms, health history, daily abilities, and examination findings.
What happens during the clinical evaluation?
The clinician takes a medical, psychiatric, medication, and symptom history. They also assess cognition, behavior, and the person's ability to manage routine activities.
Input from a family member or care partner can reveal changes that are difficult to capture during an office visit. According to the Alzheimer's Association's diagnostic testing overview, this broader assessment helps establish both cognitive decline and its effect on daily life. For the appointment, it can help to bring:.
- A current medication list
- A description of when symptoms began
- Examples of changes in routine activities
- A family member or care partner who knows the person well
- Information about mood, sleep, alcohol use, and recent illness
Which other causes need to be checked?
Some conditions can cause or worsen dementia-like symptoms. The evaluation should consider depression, untreated sleep apnea, delirium, medication effects, thyroid disease, vitamin deficiencies, and excessive alcohol use. A physical and neurologic examination may uncover signs associated with stroke, Parkinson's disease, tumors, or normal-pressure hydrocephalus.
Routine laboratory testing can also help identify alternative explanations for cognitive symptoms. This part of the work-up is important even when dementia seems possible. Finding a treatable contributor may change the diagnosis, treatment plan, or both.
Will an MRI or CT scan diagnose Alzheimer's disease?
Usually not. Structural brain imaging, commonly MRI or CT, can detect strokes, tumors, head-trauma damage, or excess fluid that may cause or contribute to cognitive symptoms.
A scan can clarify the clinical picture, but it does not establish Alzheimer's disease by itself. Its findings must be interpreted alongside the history, examinations, cognitive testing, and functional assessment.
When are specialists or Alzheimer biomarkers appropriate?
Referral to neurology, geriatrics, or neuropsychology is especially appropriate when the diagnosis remains unclear or symptoms are unusual. Referral may also help when behavioral or psychiatric symptoms are prominent, symptoms begin before age 65, or the patient or family wants a second opinion. If Alzheimer's disease remains uncertain after specialist evaluation, amyloid or tau PET imaging may sometimes clarify diagnosis and management.
The 2025 Alzheimer's Association and Society of Nuclear Medicine and Molecular Imaging criteria say PET should complement a comprehensive assessment and be ordered only when its result could change care under the updated appropriate-use criteria. Blood-based Alzheimer biomarkers are not a stand-alone response to an abnormal MMSE. The Alzheimer's Association's 2025 clinical practice guideline applies to people with objective cognitive impairment in specialized care and recommends testing only after comprehensive evaluation; its support for triage testing is conditional and based on low-certainty evidence.
